MaxCyte Inc - Asset Resilience Ratio
MaxCyte Inc (MXCT) has an Asset Resilience Ratio of 43.45% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check MaxCyte Inc strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how MaxCyte Inc's Asset Resilience Ratio has changed over time. See MaxCyte Inc balance sheet quality to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down MaxCyte Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see MaxCyte Inc (MXCT) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $92.75 Million | 43.45% |
| Total Liquid Assets | $92.75 Million | 43.45% |
Asset Resilience Insights
- Very High Liquidity: MaxCyte Inc maintains exceptional liquid asset reserves at 43.45% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
MaxCyte Inc Industry Peers by Asset Resilience Ratio
Compare MaxCyte Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Cochlear Ltd
AU:COH |
Medical Devices | 9.76% |
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 39.15% |
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
|
Polynovo Ltd
AU:PNV |
Medical Devices | 0.04% |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317 |
Medical Devices | 10.88% |
|
Dirui Industrial Co Ltd
SHE:300396 |
Medical Devices | 6.89% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
Annual Asset Resilience Ratio for MaxCyte Inc (2018–2024)
The table below shows the annual Asset Resilience Ratio data for MaxCyte Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 52.87% | $126.60 Million | $239.47 Million | +7.47pp |
| 2023-12-31 | 45.39% | $121.78 Million | $268.27 Million | -30.05pp |
| 2022-12-31 | 75.45% | $216.28 Million | $286.65 Million | +2.50pp |
| 2021-12-31 | 72.95% | $207.26 Million | $284.12 Million | +42.03pp |
| 2020-12-31 | 30.91% | $16.01 Million | $51.78 Million | +25.92pp |
| 2019-12-31 | 5.00% | $1.50 Million | $29.99 Million | -8.15pp |
| 2018-12-31 | 13.15% | $3.19 Million | $24.27 Million | -- |
About MaxCyte Inc
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based … Read more